Over the past few decades, attention in Oncology research has been shifting from a tumor-based approach to biomarker targeting for novel treatments. This shift has significant implications for disease definition, diagnosis, and treatment. In this webinar we explore the effects of this shift on clinical research in oncology and highlight some trends in clinical trial design that address changes to this field of research.

Key topics

In this webinar we will provide examples of:

• Biomarker-driven subpopulation analysis
• Population enrichment based on interim results
• Platform trials

Speakers

• Boaz Adler, Director of Global Product Engagement
• Valeria Mazzanti, Associate Director of Customer Success